Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement

JACC: Cardiovascular Interventions

Volumn 10, Issue 1, 2017, Pages 66-74

  Seeger, Julia ^a   Gonska, Birgid ^a   Rodewald, Christoph ^a   Rottbauer, Wolfgang ^a   Wöhrle, Jochen ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

anticoagulation; atrial fibrillation; non vitamin K antagonist; TAVR

Indexed keywords

APIXABAN; PHENPROCOUMON; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP;

AGED; ARTICLE; ATRIAL FIBRILLATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL OUTCOME; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINUS RHYTHM; TRANSCATHETER AORTIC VALVE IMPLANTATION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; FEMORAL ARTERY; KAPLAN MEIER METHOD; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PUNCTURE; REGISTER; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DISEASE-FREE SURVIVAL; FACTOR XA INHIBITORS; FEMALE; FEMORAL ARTERY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PHENPROCOUMON; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PUNCTURES; PYRAZOLES; PYRIDONES; REGISTRIES; RISK FACTORS; STROKE; TIME FACTORS; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME; VITAMIN K;

EID: 85007485834     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.10.023     Document Type: Article

References (26)

1. 1 Thourani, V.H., Kodali, S., Makkar, R.R., et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 387 (2016), 2218–2225.
2. 2 Leon, M.B., Smith, C.R., Mack, M.J., Makkar, R.R., et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374 (2016), 1609–1620.
3. 3 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
4. 4 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
5. 5 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban1 versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
6. 6 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
7. 7 Makkar, R.R., Fontana, G., Jilaihawi, H., et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373 (2015), 2015–2024.
8. 8 Latib, A., Naganuma, T., Abdel-Wahab, M., et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv, 8, 2015, e001779.
9. 9 European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm, A.J., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31 (2010), 2369–2429.
10. 10 Lip, G.Y., Frison, L., Halperin, J.L., Lane, D.A., Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41 (2010), 2731–2738.
11. 11 Kappetein, A.P., Head, S.J., Généreux, P., et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60 (2012), 1438–1454.
12. 12 Kodali, S.K., Williams, M.R., Smith, C.R., et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 366 (2012), 1686–1695.
13. 13 Yakubov, S.J., Adams, D.H., Watson, D.R., et al. 2-Year outcomes after iliofemoral self-expanding transcatheter aortic valve replacement in patients with severe aortic stenosis deemed extreme risk for surgery. J Am Coll Cardiol 66 (2015), 1327–1334.
14. 14 Tarantini, G., Mojoli, M., Windecker, S., et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry. J Am Coll Cardiol Intv 9 (2016), 937–946.
15. 15 Jørgensen, T.H., Thygesen, J.B., Thyregod, H.G., Svendsen, J.H., Søndergaard, L., New-onset atrial fibrillation after surgical aortic valve replacement and transcatheter aortic valve implantation: a concise review. J Invasive Cardiol 27 (2015), 41–47.
16. 16 Stortecky, S., Windecker, S., Stroke: an infrequent but devastating complication in cardiovascular interventions. Circulation 126 (2012), 2921–2924.
17. 17 Yankelson, L., Steinvil, A., Gershovitz, L., et al. Atrial fibrillation, stroke, and mortality rates after transcatheter aortic valve implantation. Am J Cardiol 114 (2014), 1861–1866.
18. 18 Barbash, I.M., Minha, S., Ben-Dor, I., et al. Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 85 (2015), 468–477.
19. 19 Nuis, R.J., Van Mieghem, N.M., Schultz, C.J., et al. Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol 109 (2012), 1637–1643.
20. 20 Chopard, R., Teiger, E., Meneveau, N., et al. Baseline characteristics and prognostic implications of pre-existing and new-onset atrial fibrillation after transcatheter aortic valve implantation: results from the FRANCE-2 registry. J Am Coll Cardiol Intv 8 (2015), 1346–1355.
21. 21 Avezum, A., Lopes, R.D., Schulte, P.J., et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 132 (2015), 624–632.
22. 22 Kannel, W.B., Wolf, P.A., Benjamin, E.J., Levy, D., Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82:suppl (1998), 2N–9N.
23. 23 Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (2013 Sep 26), 1206–1214.
24. 24 Mérie, C., Køber, L., Skov Olsen, P., et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 308 (2012), 2118–2125.
25. 25 Généreux, P., Cohen, D.J., Mack, M., et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol 64 (2014), 2605–2615.
26. 26 Yadlapati, A., Groh, C., Malaisrie, S.C., Gajjar, M., Kruse, J., Meyers, S., Passman, R., Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol 105 (2016), 268–272.